CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase I Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. announced that TriStar Centennial Medical Center, through Sarah Cannon Research Institute, in Nashville, Tennessee, is a clinical trial site for the Company’s Phase I clinical of CER-1236.